"At the end of the day, however suboptimal it is in functioning, it is still the only multilateral game in town. But when it doesn't step up on key issues, countries figure out their own ways of doing it," Jaishankar said.
Director General, ICMR, Rajiv Bahl, has written a letter to the authors of the paper and editor of the journal Springer Nature to immediately remove the acknowledgement to ICMR and publish an erratum. He also flagged the poor methodology and design of the study.
Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first."
Mumbai (Maharashtra) [India], January 25: As the nation gears up to celebrate Republic Day, Star Gold takes immense pride in presenting the world television premiere of 'The Vaccine War'- a cinematic journey that encapsulates India's triumphant battle against the COVID-19 pandemic through th
From technological advancements to social campaigns, Jaishankar painted a vivid picture of a progressing India, urging the diaspora to convey this narrative to the world.
Bharat Biotech is a world-leading vaccine and biotherapeutics manufacturer. During the Covid pandemic, it made the vaccine Covaxin, which was administered by millions across the globe
New Delhi [India], August 9: TRIMACARE, India's first prenatal pregnancy supplement based on the Multi-Micronutrient model (MMN), has been granted a patent, heralding a new era in prenatal care and marking a significant milestone in the vast Indian pregnancy market.
The Central drug regulatory authority Drugs Controller General of India (DCGI) has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for those who have already taken two doses of Covishield or Covaxin.
A release said that Covaxin has been demonstrated in clinical trials to generate a broader immune response "against the whole virus covering important antigens such as S-protein, RBD, and N-protein whereas currently approved vaccines in the US target only S-protein antigen"